Galapagos raising cash for new buyouts

Belgium's Galapagos is raising about $43 million in a new offering designed to help fund new acquisitions. Galapagos bought Argenta earlier this year for €16.5 million. "Management also remains ambitious to make Galapagos a European biotech leader, and acquisitions may help us to achieve that goal," said CEO Onno van de Stolpe. Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.